The GenTAC Alliance is a community of stakeholders committed to advancing our understanding of genetic thoracic aortic diseases and their treatment.
The Alliance builds upon the successes of the GenTAC Registry, which enrolled and followed participants from 2006 to 2016 and seeks to involve a much wider group of stakeholders and be more expansive in scope.
The goals of the GenTAC Alliance are to advance basic, translational and clinical research; educate and support patients, families, and clinicians; and coordinate, facilitate, and encourage the use of biospecimens and data across registries.
In light of the current public health crisis due to COVID-19, the GenTAC Alliance is committed to connecting the Genetic Thoracic Aortic disease community to the most up to date research and information. Please see our COVID-19 updates page for information and guidance.GenTAC COVID-19 Guidance
In this week's tip, Dr. Kim Eagle discusses the importance of continuing use of prescribed angiotosin receptor blocking medication (such as losartan, irbesartan, valsartan, olmesartan, telmisartan) and ACE inhibitors (lisinopril, enalapril, captopril, ramipriland), despite early reports that these medications may increase risk or severity of COVID-19.
The Alliance welcomes patients, families, clinicians, researchers, and advocacy organizations to join our community of stakeholders in promoting and enhancing collaboration in education, research, and care with regard to genetically-triggered thoracic aortic disease and related cardiac and non-cardiac complications.Learn More
On Wednesday, May 13, 2020 experts from the GenTAC Basic and Translational Science Working Group met for a webinar on methods and results for single cell sequencing of aortic tissues.Announcements
Check here for updates on the Alliance and global events related to thoracic aortic disease.
Find the latest research regarding thoracic aortic disease.
Learn about GenTAC related patient registries and their work.